Watch out – this SAP NetWeaver bug has a maximum severity score, and it could target your servers next TechRadar

Novo Nordisk Gets New Complement System Approach to Rare Diseases With Deal for Omeros Drug
Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused